Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia

Inclusion Criteria

- Patients in the following disease categories will be considered eligible for this
study: *Any acute leukemia beyond an initial attempt to induce a remission or after
relapse, *Chronic Myelogenous Leukemia in Blast Phase, *Refractory Multiple Myeloma,
*Refractory non-Hodgkin's and Hodgkin's Lymphoma

- Patients must be more than 14 days beyond prior myelotoxic chemotherapy.

- Several other eligibility criteria apply.